Abstract
Understanding the key characteristics of malaria testing and treatment is essential to the control of a disease that continues to pose a major risk of morbidity and mortality in mainland Tanzania, with evidence of a resurgence of the disease in recent years. The introduction of artemisinin combination therapy (ACT) as the first-line treatment for malaria, alongside policies to promote rational case management following testing, highlights the need for evidence of anti-malarial and testing markets in the country. The results of the most recent mainland Tanzania ACTwatch outlet survey are presented here, including data on the availability, market share and price of anti-malarials and malaria diagnosis in 2016. A nationally-representative malaria outlet survey was conducted between 18th May and 2nd July, 2016. A census of public and private outlets with potential to distribute malaria testing and/or treatment was conducted among a representative sample of administrative units. An audit was completed for all anti-malarials, malaria rapid (RDT) diagnostic tests and microscopy. A total of 5867 outlets were included in the nationally representative survey, across both public and private sectors. In the public sector, availability of m...Continue Reading
References
Jan 30, 2010·Lancet·Mohga Kamal-Yanni
Mar 9, 2010·BMJ : British Medical Journal·Evelyn K AnsahChristopher J M Whitty
Jun 11, 2011·Health Research Policy and Systems·Edmund RuttaHiiti Sillo
Aug 20, 2011·Malaria Journal·Shunmay YeungDuong Socheat
Nov 2, 2011·Malaria Journal·Tanya ShewchukDesmond Chavasse
Nov 2, 2011·Malaria Journal·Kathryn A O'ConnellDesmond Chavasse
Jun 14, 2012·International Journal for Equity in Health·Marinka van der HoevenMinrie Greeff
Nov 6, 2012·Lancet·Sarah TougherKara Hanson
Feb 7, 2013·Malaria Journal·Kathryn A O'ConnellCatherine Goodman
Feb 14, 2013·Drug, Healthcare and Patient Safety·Om Minzi, Vs Manyilizu
Feb 19, 2013·Trends in Parasitology·V Bhargavi RaoAzra C Ghani
Jun 7, 2013·Malaria Journal·Wendy Prudhomme O'MearaBarasa Khwa-Otsyula
Sep 17, 2013·Drug, Healthcare and Patient Safety·Appolinary Ar Kamuhabwa, Richard Silumbe
Oct 29, 2013·BMC Health Services Research·Inez Mikkelsen-LopezDon de Savigny
Dec 20, 2013·BMC Health Services Research·Peter S LarsonJessica L Cohen
Feb 6, 2014·Malaria Journal·Barbara A WilleyCatherine Goodman
May 13, 2014·PloS One·Rebecca ThomsonCatherine Goodman
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Mar 6, 2015·BMJ : British Medical Journal·Evelyn K AnsahChristopher J M Whitty
Nov 18, 2015·Malaria Journal·Anthony K MbonyePascal Magnussen
Mar 10, 2016·Malaria Journal·Richard M Oxborough
Apr 10, 2016·Malaria Journal·UNKNOWN ACTwatch GroupHuy Rekol
Apr 27, 2016·Malaria Journal·Andrew RamsayJohn C Reeder
Jan 5, 2017·Malaria Journal·Kathleen MaloneySigsbert Mkude
Apr 27, 2017·Malaria Journal·UNKNOWN ACTwatch GroupCatherine Goodman
Citations
Dec 23, 2017·Malaria Journal·UNKNOWN ACTwatch GroupEdward Abwao
Sep 8, 2018·PloS One·Joanna GallayBlaise Genton
Jun 4, 2019·PloS One·Marceline F FindaFredros O Okumu
Sep 8, 2017·BMC Research Notes·Elinas J NnkoEliningaya J Kweka
Jun 6, 2019·PloS One·Arthur MpimbazaAnne Katahoire
Aug 21, 2020·The Journal of Clinical Hypertension·Karl G ReisRobert N Peck
May 31, 2018·Malaria Journal·Dejan ZurovacEjersa Waqo
Feb 13, 2020·Malaria Journal·Manase KilonziAppolinary Kamuhabwa
Mar 10, 2020·Journal of Tropical Medicine·Adela BudimuDebora C Kajeguka
May 23, 2018·Malaria Journal·Joanna GallayEmilie Pothin
Nov 28, 2019·Malaria Journal·Billy Ngasala, Samweli Bushukatale